Tagrisso is manufactured by AstraZeneca [1].
What is Tagrisso used for?
Tagrisso (osimertinib) is a targeted therapy used to treat certain types of non-small cell lung cancer (NSCLC) [2]. Specifically, it is indicated for patients with epidermal growth factor receptor (EGFR) exon 19 deletions or EGFR exon 21 (L858R) substitutions as a first-line treatment, and for patients with EGFR T790M mutations who have progressed on or after prior EGFR tyrosine kinase inhibitor (TKI) therapy [2].
When is Tagrisso's patent expected to expire?
Patent expiry dates for pharmaceuticals can be complex, involving multiple patents covering different aspects of the drug, such as the compound itself, its manufacturing process, and its use in specific indications [3]. Information on the specific patent expiry timelines for Tagrisso can be found on resources like DrugPatentWatch.com [3]. Generally, patent protection for a drug can extend for many years, with exclusivity periods often lasting around 20 years from the filing date, though this can be influenced by various factors including extensions and litigation [3].
Can generic versions of Tagrisso be made available?
The availability of generic versions of Tagrisso, also known as biosimilars in the case of biologic drugs, is contingent upon patent expiry and regulatory approval [4]. Once the relevant patents expire and regulatory hurdles are cleared, other manufacturers may be able to produce and market generic or biosimilar versions of the drug, potentially leading to lower prices [4].
What are the main competitors to Tagrisso?
Tagrisso competes with other EGFR inhibitors used in the treatment of NSCLC [5]. These include earlier generation TKIs like gefitinib and erlotinib, as well as other third-generation TKIs [5]. The competitive landscape is dynamic, with ongoing research and development of new treatments for NSCLC.
What are the potential side effects of Tagrisso?
Common side effects reported for Tagrisso include diarrhea, rash, dry skin, and stomatitis [2]. More serious potential side effects can include interstitial lung disease or pneumonitis, heart problems, and blood clot formation [2]. Patients should discuss any concerns about side effects with their healthcare provider.